Streetbeat News

Regulatory

BAK

Braskem (NYSE:BAK) has been awarded a $671,000 grant from the REMADE Institute, funded by the U.S. Department of Energy, for its polymer recycling technology research partnership. The project, in collaboration with the University of Massachusetts Lowell, Dow Chemical, and Aquapak, aims to develop advanced manufacturing technology for sustainable and recyclable multilayer plastic films. Braskem's goal is to include 300,000 tons of recycled content in its products by 2025 and 1 million tons by 2030, while also reducing greenhouse gas emissions. The REMADE Institute has funded nearly 100 R&D projects since 2017, focusing on reducing energy and emissions in industrial materials production.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:16 pm

MA

Mastercard Inc (NYSE:MA) has partnered with Feedzai to enhance its capabilities in combating crypto fraud using AI. The collaboration will integrate Feedzai with Mastercard's CipherTrace Armade platform, allowing banks to monitor transactions from over 6,000 crypto exchanges for fraudulent and suspicious activities. This initiative is part of Mastercard's effort to normalize crypto as a financial asset, subject to traditional regulatory frameworks. The company's data indicates that crypto transaction fraud is five times higher than that of fiat transactions. Despite this move, a Mastercard executive recently criticized the use of central bank digital currencies (CBDCs), citing a lack of justification for their widespread adoption. Mastercard's stock (MA) saw a slight increase of 0.12% to $400.80 in premarket trading.

Portfolio Pulse from Lekha Gupta

November 20, 2023 | 1:16 pm

JNJ

Janssen, part of Johnson & Johnson, submitted a supplemental Biologics License Application to the FDA for RYBREVANT combined with chemotherapy to treat EGFR-mutated non-small cell lung cancer post-osimertinib. The submission is based on Phase 3 MARIPOSA-2 study results, which showed improved progression-free survival compared to chemotherapy alone. The study was presented at the ESMO 2023 Congress and published in Annals of Oncology. RYBREVANT previously received accelerated FDA approval for NSCLC with EGFR exon 20 insertion mutations.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:15 pm

SPEC

Spectaire Holdings Inc has entered into a $20M common stock purchase agreement with an equity line investor, as disclosed in their SEC 8K filing on November 17.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:15 pm

FXI

SPY

VGK

Treasury Secretary Yellen emphasized the critical dependence of Ukraine on U.S. aid and the importance of providing assistance to both Ukraine and Israel. She also highlighted the need for a sustainable and fiscally responsible approach to U.S. spending and taxation.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:14 pm

FXI

SPY

VGK

Treasury Secretary Janet Yellen stated that the Biden Administration is focusing on investments to enhance conditions across the U.S. Additionally, she emphasized that providing aid to Ukraine is a critical priority for the Biden Administration due to its national security implications, underscoring the importance of ensuring Ukraine does not lose the battle on its home front.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:13 pm

BCLI

BrainStorm Cell Therapeutics has scheduled an in-person meeting with the FDA on December 6 to discuss a confirmatory Phase 3 trial for NurOwn, its treatment for ALS. The company aims to seek a Special Protocol Assessment (SPA) for the trial.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:12 pm

FXI

SPY

Treasury Secretary Janet Yellen acknowledged that Americans are still experiencing rising costs in key areas such as food. She emphasized the necessity to communicate the economic improvements made under President Biden's administration.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:12 pm

FXI

SPY

Treasury Secretary Yellen expressed concerns about privacy issues with social media and acknowledged that these matters are unresolved. She also noted progress in reducing inflation.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:11 pm

ASND

Ascendis Pharma has received approval from the European Commission for YORVIPATH, a treatment for adults with chronic hypoparathyroidism. This marks a significant milestone for the company as it expands its product offerings in the European market.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:05 pm